Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QNTM
stocks logo

QNTM

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Valuation Metrics

The current forward P/E ratio for Quantum Biopharma Ltd (QNTM.O) is 0.00, compared to its 5-year average forward P/E of -1.71. For a more detailed relative valuation and DCF analysis to assess Quantum Biopharma Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.71
Current PE
0.00
Overvalued PE
0.93
Undervalued PE
-4.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.68
Current PS
0.48
Overvalued PS
1.56
Undervalued PS
-0.19

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

QNTM News & Events

Events Timeline

(ET)
2025-08-07
07:14:39
Quantum Group reports Q2 operating expenses $4.9M vs $3.4M last quarter
select
2025-08-05 (ET)
2025-08-05
07:36:57
Quantum Group subsidiary received CSR for Phase 1 MAD trial
select
2025-08-04 (ET)
2025-08-04
07:37:33
Quantum Group files reply, provides update on court case against CIBC, RBC
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
08-07Newsfilter
PinnedQuantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

  • Financial Performance: Quantum BioPharma reported strong financial results for Q2 2025, with increased assets, elimination of debt through equity conversion, and a significant rise in stock price from $7.71 to $20.25 USD, while maintaining sufficient cash reserves to support operations beyond March 2027.

  • Drug Development Progress: The company is advancing its multiple sclerosis drug, Lucid-MS, which has shown no toxicity in Phase 1 studies, and has partnered with Massachusetts General Hospital for innovative PET imaging studies to monitor demyelination, alongside ongoing efforts to commercialize its alcohol detoxification product, unbuzzd.

Preview
9.0
08-05Newsfilter
PinnedQuantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

  • Clinical Trial Results: Quantum BioPharma's subsidiary, Huge Biopharma Australia, announced that the clinical study report for Lucid-MS showed no safety or tolerability concerns in healthy participants during a Phase 1 trial, allowing advancement to efficacy trials for multiple sclerosis patients.

  • Company Overview: Quantum BioPharma focuses on innovative biopharmaceutical solutions for neurodegenerative disorders and retains significant ownership in Unbuzzd Wellness Inc., alongside strategic investments through its subsidiary, FSD Strategic Investments Inc.

Preview
9.0
08-06Benzinga
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug

  • Clinical Trial Success: Quantum Biopharma Ltd.'s subsidiary, Huge Biopharma Australia, has received a clinical study report confirming that its compound Lucid-MS is safe and tolerable in healthy adults, allowing for further development towards treating multiple sclerosis.

  • Stock Performance: Following the positive trial results, QNTM stock has seen significant growth over the past year, although it experienced an 8.63% decline recently, trading at $25.40.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Quantum Biopharma Ltd (QNTM) stock price today?

The current price of QNTM is 26.01 USD — it has decreased -0.5 % in the last trading day.

arrow icon

What is Quantum Biopharma Ltd (QNTM)'s business?

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

arrow icon

What is the price predicton of QNTM Stock?

Wall Street analysts forecast QNTM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNTM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Quantum Biopharma Ltd (QNTM)'s revenue for the last quarter?

Quantum Biopharma Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Quantum Biopharma Ltd (QNTM)'s earnings per share (EPS) for the last quarter?

Quantum Biopharma Ltd. EPS for the last quarter amounts to -3.47 USD, increased 1.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Quantum Biopharma Ltd (QNTM)'s fundamentals?

The market is revising No Change the revenue expectations for QNTM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 197.60%.
arrow icon

How many employees does Quantum Biopharma Ltd (QNTM). have?

Quantum Biopharma Ltd (QNTM) has 0 emplpoyees as of August 08 2025.

arrow icon

What is Quantum Biopharma Ltd (QNTM) market cap?

Today QNTM has the market capitalization of 99.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free